Daniel B. Costa
Expertise in
13
conditions

Dr. Daniel B. Costa

Internal Medicine | Oncology
330 Brookline Avenue, Shapiro 9, 
Boston, MA 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
13
conditions
330 Brookline Avenue, Shapiro 9, 
Boston, MA 

Overview

Daniel Costa is an Internal Medicine specialist and an Oncologist in Boston, Massachusetts. Dr. Costa is highly rated in 13 conditions, according to our data. His top areas of expertise are EGFR Positive Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma.

His clinical research consists of co-authoring 156 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

University Of Sao Paulo - Faculdade De Medicina De Ribeirao Preto

Residency

Hospital of FHRP, University of Sao Paulo

Specialties

Internal Medicine
Oncology

Licenses

Internal Medicine in MA

Board Certifications

American Board Of Internal Medicine

Fellowships

Beth Israel Deaconess Medical Center

Hospital Affiliations

Beth Israel Deaconess Medical Center

Languages Spoken

English
Portuguese

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Senior Whole Health
  • MEDICARE-MEDICAID PLAN
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Shapiro 9, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Drug: APL-101
Study Phase: Phase 2
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: February 09, 2026
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 3
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: Osimertinib, Selumetinib
Study Phase: Phase 2
A Phase I/II Trial to Evaluate the Safety and Tolerability of Alectinib and Bevacizumab in Patients With Advanced, ALK-Positive, Non-Small Cell Lung Cancer
A Phase I/II Trial to Evaluate the Safety and Tolerability of Alectinib and Bevacizumab in Patients With Advanced, ALK-Positive, Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: May 13, 2025
Intervention Type: Drug
Study Drugs: Alectinib, Bevacizumab
Study Phase: Phase 1/Phase 2
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Cisplatin, Carboplatin
Study Phase: Phase 3
A Phase 1/2 Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
A Phase 1/2 Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
Enrollment Status: Terminated
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer
A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: November 04, 2020
Intervention Type: Drug
Study Phase: Phase 2
Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation
Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation
Enrollment Status: Unknown
Publish Date: July 07, 2020
Intervention Type: Drug
Study Drug: Afatinib
Study Phase: Phase 2
Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
Enrollment Status: Terminated
Publish Date: November 22, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Trial of Sunitinib in Never-smokers With Lung Adenocarcinoma: Identification of Oncogenic Alterations Underlying Sunitinib Sensitivity
A Phase II Trial of Sunitinib in Never-smokers With Lung Adenocarcinoma: Identification of Oncogenic Alterations Underlying Sunitinib Sensitivity
Enrollment Status: Completed
Publish Date: October 31, 2018
Intervention Type: Drug
Study Phase: Phase 2
Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Enrollment Status: Completed
Publish Date: April 10, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

156 Total Publications

Improving Prostate MRI: Lessons Learned from the American College of Radiology's Prostate MR Image Quality Improvement Collaborative.
Improving Prostate MRI: Lessons Learned from the American College of Radiology's Prostate MR Image Quality Improvement Collaborative.
Journal: Radiographics : a review publication of the Radiological Society of North America, Inc
Published: December 04, 2025
Similar Doctors
Expertise in
21
conditions
Dr. Matthew Davids
Oncology
Expertise in
21
conditions
Dr. Matthew Davids
Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.2 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matthew Davids is an Oncologist in Boston, Massachusetts. Dr. Davids is highly rated in 21 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Tissue Biopsy, and Bone Marrow Transplant.

Expertise in
44
conditions
Dr. Eric Jacobsen
Oncology
Expertise in
44
conditions
Dr. Eric Jacobsen
Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.2 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eric Jacobsen is an Oncologist in Boston, Massachusetts. Dr. Jacobsen is highly rated in 44 conditions, according to our data. His top areas of expertise are Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
28
conditions
Dr. Jeremy Abramson
Oncology
Expertise in
28
conditions
Dr. Jeremy Abramson
Oncology

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (2.5 miles away)
617-724-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeremy Abramson is an Oncologist in Boston, Massachusetts. Dr. Abramson is highly rated in 28 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Daniel B. Costa

How do I make an appointment with Dr. Daniel B. Costa?

You can book an appointment with Dr. Daniel B. Costa by calling their office at 617-667-9236. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel B. Costa a top-rated expert for EGFR Positive Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel B. Costa is classified as an Elite expert for EGFR Positive Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel B. Costa specialize in?

While Dr. Daniel B. Costa is a Internal Medicine, they have specific expertise in EGFR Positive Lung Cancer, Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Daniel B. Costa participate in research or clinical trials?

Yes. Dr. Daniel B. Costa has published 156 articles and abstracts on conditions like EGFR Positive Lung Cancer. You can view a list of Dr. Daniel B. Costa's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daniel B. Costa accept my insurance?

Dr. Daniel B. Costa accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 617-667-9236 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Costa's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 7 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile